Advanced search
Publication Cover
Clinical Ophthalmology Volume 4, 2010 - Issue
Submit an article Journal homepage
88
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy

Norbert Pfeiffer1 Johannes Gutenberg-Universität Mainz, Mainz, Germany
,
Maria-Luise Scherzer2 Regenstauf, Germany
,
Hubert Maier3 Gerolzhofen, Germany
,
Sonja Schoelzel4 Institutes of Molecular Medicine, University of Freiburg, Department of Surgery, Freiburg, Germany
,
Mark C Jasek5 Alcon Laboratories, Inc., Fort Worth, TX, USA
,
Jeanette A Stewart6 PRN Pharmaceutical Research Network, LLC, Charleston, SC, USA
&
William C Stewart6 PRN Pharmaceutical Research Network, LLC, Charleston, SC, USACorrespondence[email protected]
 show all
Pages 459-466 | Published online: 06 May 2010

References

  • BarnebeyHSOrengo-NaniaSFlowersBEThe safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solutionAm J Ophthalmol200514011715990081
  • SilvermanSLFrom randomized controlled trials to observational studiesAm J Med2009122211412019185083
  • FletcherAEControversy over “contradiction”: should randomized trials always trump observational studies?Am J Ophthalmol2009147338438619217953
  • BookSAEssentials of StatisticsNew York, NYMcGraw Hill Book Company1978117122205215
  • DuffGRA double-masked crossover study comparing the effects of carteolol 1% and 2% on intraocular pressureActa Ophthalmologica19876556186213321878
  • MillerRGBeyond ANOVA: Basics of Applied StatisticsNew York, NYChapman and Hall/CRC19987476
  • SiegelSNonparametric Statistics for the Behavioral SciencesNew York, NYMcGraw Hill Book Company19566367
  • ZimmermanTJStewartWCfor Latanoprost AXIS Study GroupIntraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from monotherapy treatmentsJ Ocul Pharmacol Ther200319540541514583133
  • HamacherTSchinzelMSchölzel-KlattAShort-term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from mono- and adjunctive therapiesBr J Ophthalmol200488101295129815377554
  • KonstasAGPBányaiLBlaskK-DIntraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapiesJ Ocul Pharmacol Ther200420537538215650512
  • HaverkampFWuenschSFuchsMStewartWCIntraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatmentsEur J Ophthalmol200414540741515506603
  • BayerAWeilerWOeverhausUTwo-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapiesJ Ocul Pharmacol Ther200420647047815684807
  • DunkerSSchmuckerAMaierHTolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timololAdv Ther200724237638617565929
  • TakahashiITanakaMSwitching to latanoprost monotherapy for 24 weeks in glaucoma patientsEur J Ophthalmol200414540140615506602

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.